# Precious3GPT Aging Research Agent

**ID:** `biomedical.longevity.precious3gpt`
**Version:** 1.0.0
**Status:** Experimental
**Category:** Longevity / AI Research

---

## Overview

The **Precious3GPT Aging Research Agent** integrates Precious3GPT (P3GPT), the first transformer model specifically designed for drug and biomarker discovery in aging research. P3GPT is a multi-modal, multi-omics, multi-species foundation model that leverages Retrieval-Augmented Generation (RAG) to maintain up-to-date integration with peer-reviewed aging literature.

This conversational agent allows researchers to query aging-related knowledge across species, cell types, pathways, and therapeutic interventions.

---

## Key Capabilities

### 1. Multi-Species Analysis

| Species | Data Available | Applications |
|---------|---------------|--------------|
| **Human** | Omics, clinical, epidemiological | Translational research |
| **Mouse** | Lifespan, healthspan, omics | Preclinical validation |
| **C. elegans** | Lifespan, genetic screens | High-throughput discovery |
| **D. melanogaster** | Lifespan, behavior | Genetic studies |
| **Yeast** | Replicative/chronological lifespan | Mechanism discovery |

### 2. Query Types

| Query Category | Examples |
|----------------|----------|
| **Gene function** | "What is the role of SIRT1 in aging?" |
| **Drug prediction** | "Predict compounds that extend mouse lifespan" |
| **Biomarker discovery** | "Identify aging biomarkers in blood" |
| **Pathway analysis** | "How does mTOR signaling affect longevity?" |
| **Cross-species** | "Compare insulin signaling aging effects across species" |

### 3. RAG-Enhanced Knowledge

- **PubMed integration:** Real-time literature updates
- **DrugAge database:** Known geroprotectors
- **GenAge database:** Aging-related genes
- **LongevityMap:** Human longevity variants
- **CellAge:** Cellular senescence genes

### 4. Prediction Capabilities

- **Lifespan prediction:** Gene/drug effects on longevity
- **Healthspan biomarkers:** Functional aging metrics
- **Drug-gene interactions:** Aging pathway modulation
- **Species translation:** Cross-species effect prediction

---

## Usage

### Example Prompt

```text
Query Precious3GPT:

"What are the top 10 genes that, when overexpressed, extend lifespan
in both mice and C. elegans? For each gene, suggest a pharmacological
approach to mimic the overexpression effect."
```

### Expected Output

```
## P3GPT Query Response: Longevity Genes

### Query Analysis
- **Species filter:** Mouse AND C. elegans
- **Intervention:** Overexpression (gain-of-function)
- **Outcome:** Lifespan extension
- **Request:** Pharmacological mimetics

### Top 10 Conserved Longevity Genes

| Rank | Gene (Human) | Mouse Effect | C. elegans Effect | Conservation |
|------|--------------|--------------|-------------------|--------------|
| 1 | **SIRT1/sir-2.1** | +15-20% | +50% | Very high |
| 2 | **FOXO3/daf-16** | +10-15% | +100%+ | Very high |
| 3 | **AMPK/aak-2** | +10-15% | +15-30% | High |
| 4 | **ATG5/bec-1** | +10% | +15% | High |
| 5 | **SOD2/sod-3** | +5-10% | +30% | Moderate |
| 6 | **NRF2/skn-1** | +10% | +20% | High |
| 7 | **PGC1α/N/A** | +15% | N/A (mouse-specific) | - |
| 8 | **TFEB/hlh-30** | +10% | +25% | High |
| 9 | **HSF1/hsf-1** | +5% | +20% | Moderate |
| 10 | **CISD2/cisd-3.2** | +12% | +15% | Moderate |

### Detailed Analysis with Drug Mimetics

#### 1. SIRT1/sir-2.1 (NAD+-dependent deacetylase)

**Mechanism:**
- Deacetylates FOXO, PGC-1α, p53
- Promotes metabolic efficiency
- Enhances stress resistance

**Pharmacological Mimetics:**
| Drug | Mechanism | Status | Effect |
|------|-----------|--------|--------|
| **NAD+ precursors (NMN, NR)** | Increase SIRT1 activity | Trials | +10-15% lifespan (mice) |
| **Resveratrol** | Allosteric SIRT1 activator | Trials | Variable |
| **SRT1720** | Direct SIRT1 activator | Preclinical | +8% lifespan (mice) |

**Recommendation:** NMN (500mg/day) - most promising clinical translation

#### 2. FOXO3/daf-16 (Transcription factor)

**Mechanism:**
- Master longevity regulator
- Activates stress response genes
- Suppresses tumor growth

**Pharmacological Mimetics:**
| Drug | Mechanism | Status | Effect |
|------|-----------|--------|--------|
| **FOXO3 activating peptides** | Direct activation | Discovery | Unknown |
| **PI3K inhibitors** | Indirect FOXO activation | Approved (cancer) | Lifespan extension |
| **Rapamycin** | mTOR inhibition → FOXO | Approved | +9-14% (mice) |

**Recommendation:** Low-dose rapamycin (intermittent) - existing clinical experience

#### 3. AMPK/aak-2 (Energy sensor)

**Mechanism:**
- Master metabolic regulator
- Activates autophagy
- Inhibits mTOR

**Pharmacological Mimetics:**
| Drug | Mechanism | Status | Effect |
|------|-----------|--------|--------|
| **Metformin** | AMPK activator | Approved | Epidemiological benefit |
| **AICAR** | AMPK agonist | Research | Lifespan extension |
| **Berberine** | Natural AMPK activator | Supplement | +20% (nematodes) |

**Recommendation:** Metformin (500-1500mg/day) - extensive safety data

### Cross-Species Conservation Analysis

```
           Human    Mouse    C.elegans   Yeast
SIRT1       ●        ●          ●          ●
FOXO3       ●        ●          ●          ○
AMPK        ●        ●          ●          ●
mTOR        ●        ●          ●          ●
Autophagy   ●        ●          ●          ●

● = Strong conservation, ○ = Partial conservation
```

### Confidence Assessment

| Gene | Evidence Level | Translation Potential |
|------|---------------|----------------------|
| SIRT1 | Very Strong | High (NAD+ precursors) |
| FOXO3 | Strong | Medium (indirect activation) |
| AMPK | Very Strong | High (metformin) |
| mTOR | Very Strong | High (rapamycin) |
| NRF2 | Strong | Medium (sulforaphane) |

### Literature Support (RAG Retrieved)

1. "NAD+ supplementation extends mouse lifespan" - Science (2016)
2. "FOXO3 genotype is strongly associated with longevity" - PNAS (2008)
3. "Metformin extends mouse lifespan" - Nature Communications (2013)
4. "Rapamycin extends lifespan in genetically heterogeneous mice" - Nature (2009)

### Suggested Research Direction

**Combination therapy targeting multiple conserved pathways:**

```
AMPK activation (Metformin)
        +
mTOR inhibition (Rapamycin)
        +
NAD+ enhancement (NMN)
        ↓
    Synergistic lifespan extension
```

**Predicted combined effect:** 25-35% lifespan extension (mouse)
**Confidence:** Medium (requires experimental validation)
```

### LLM Agent Integration

```python
@tool
def query_precious3gpt(
    query: str,
    species: list[str] = ["human", "mouse"],
    include_drugs: bool = True,
    include_references: bool = True
) -> str:
    """
    Queries Precious3GPT aging research foundation model.

    Args:
        query: Natural language aging research query
        species: Species to include in analysis
        include_drugs: Include pharmacological recommendations
        include_references: Include literature citations

    Returns:
        Comprehensive aging research response with RAG citations
    """
    pass
```

---

## Prerequisites

### Required Resources

| Resource | Purpose | Access |
|----------|---------|--------|
| **Precious3GPT API** | Foundation model | Insilico Medicine |
| **GenAge** | Aging gene database | Public |
| **DrugAge** | Geroprotector database | Public |
| **PubMed** | Literature RAG | NCBI API |

---

## References

- **Galkin et al. (2023):** "Precious3GPT: A multimodal multi-species transformer for aging research." *Nature Machine Intelligence*
- **GenAge Database:** [genomics.senescence.info/genes/](https://genomics.senescence.info/genes/)
- **DrugAge Database:** [genomics.senescence.info/drugs/](https://genomics.senescence.info/drugs/)

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
